nivolumab,ipilimumab,cabozantinib
bms
['nivolumab', '/ipi', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipilimumab', 'kcsm,(-skcsm)', 'nivo']
cabozantinib plus nivolumab/ipilimumab shows notable pfs improvement in intermediate-risk, advanced rcc #gu23 #kcsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.